What is IVP in national immunization program
Reading Document
Medical Text Search
IVP Immunization Vaccines Program national immunization schedule
GradeResponse
IVP in the context of a national immunization program stands for Inactivated Viral/Poliovirus/Polio Vaccine — but the most common usage specifically is:
IVP = Immunization Value Program or, most commonly, Inactivated Polio Vaccine (IPV)
In most national immunization programs, IVP is used as an abbreviation for Inactivated Polio Vaccine (IPV), though the exact acronym may vary by country or program documentation.
Inactivated Polio Vaccine (IPV/IVP) in National Immunization Programs
What is it?
IPV (sometimes written IVP) is a killed (inactivated) poliovirus vaccine that protects against all three serotypes of poliovirus (Types 1, 2, and 3). It is one of two types of polio vaccines, the other being the Oral Polio Vaccine (OPV).
How it Works
- Contains killed poliovirus strains
- Administered via intramuscular or subcutaneous injection
- Induces humoral (blood) immunity — produces antibodies that prevent poliovirus from entering the nervous system
- Does not cause vaccine-associated paralytic poliomyelitis (VAPP), unlike OPV
Schedule in National Immunization Programs
Most countries include IPV/IVP in the routine childhood immunization schedule. A typical schedule:
| Dose | Age |
|---|---|
| 1st dose | 6–8 weeks of age |
| 2nd dose | 10–12 weeks of age |
| 3rd dose | 14–16 weeks of age |
| Booster | 18 months – 5 years |
Why IPV over OPV?
As part of the Global Polio Eradication Initiative (GPEI) and WHO recommendations, many countries have transitioned from OPV to IPV or use a combination (sequential IPV then OPV) because:
- IPV carries zero risk of VAPP
- Wild poliovirus Type 2 has been eradicated globally
- IPV provides strong systemic immunity
Role in Eradication
The WHO and UNICEF include IPV as part of the Expanded Programme on Immunization (EPI) in national immunization schedules worldwide, especially after the 2016 global switch from trivalent OPV to bivalent OPV (bOPV).
Note: If "IVP" in your context refers to a specific country's program documentation (e.g., Philippines, India, or another national EPI), the abbreviation may carry a slightly different local meaning or schedule. If you can specify the country, a more targeted answer can be provided.
AFP
Medical Text Search
AFP acute flaccid paralysis polio surveillance immunization program
GradeResponse
AFP — Acute Flaccid Paralysis
In the context of a national immunization program, AFP stands for Acute Flaccid Paralysis — a key component of polio surveillance.
What is AFP?
AFP is the sudden onset of flaccid (floppy, weak) paralysis in one or more limbs in a child under 15 years of age, or paralysis of any age where polio is suspected. It is the primary clinical indicator used worldwide to detect poliovirus circulation.
AFP Surveillance in National Immunization Programs
AFP surveillance is the gold standard for polio eradication monitoring, as recommended by the WHO and part of every national EPI (Expanded Programme on Immunization).
Why Surveillance?
- Polio causes acute flaccid paralysis by destroying anterior horn cells in the spinal cord
- Since wild poliovirus may circulate silently, monitoring every AFP case helps detect outbreaks early
- Every AFP case must be investigated as a potential polio case until proven otherwise
Case Definition
| Criteria | Detail |
|---|---|
| Age | Child < 15 years (any age if polio suspected) |
| Presentation | Sudden flaccid (not spastic) weakness/paralysis |
| Onset | Rapid — hours to a few days |
| Causes | Polio, Guillain-Barré syndrome, transverse myelitis, traumatic neuritis, enterovirus D68, etc. |
AFP Surveillance Process
- Detection — Any AFP case is reported immediately by healthcare workers
- Notification — Reported within 24–48 hours to local/national health authorities
- Investigation — Field investigation within 48 hours of notification
- Stool collection — Two stool samples collected 24–48 hours apart (within 14 days of paralysis onset) for virologic testing
- Lab testing — Samples sent to a WHO-accredited polio laboratory to isolate poliovirus
- Classification — Case classified as confirmed polio, compatible, discarded, or other AFP etiology
- 60-day follow-up — Residual paralysis assessed at 60 days post-onset
AFP Surveillance Performance Indicators
WHO sets minimum targets to assess the quality of surveillance:
| Indicator | Target |
|---|---|
| Non-polio AFP rate | ≥ 2 per 100,000 children < 15 years |
| Adequate stool specimen collection rate | ≥ 80% of AFP cases |
| Stool adequacy (2 samples within 14 days) | ≥ 80% |
Common Causes of AFP (Differential Diagnoses)
- Guillain-Barré Syndrome (GBS) — most common non-polio AFP cause
- Poliovirus (wild or vaccine-derived)
- Transverse myelitis
- Traumatic neuritis (injection injury)
- Enterovirus D68 — causes acute flaccid myelitis (AFM), affects anterior horn cells similar to polio (Harrison's, p. 6010)
- Botulism, tick paralysis
Relationship to IPV/OPV
AFP surveillance works hand-in-hand with the polio immunization program (IPV/OPV). High AFP detection rates combined with high vaccination coverage are the twin pillars of the Global Polio Eradication Initiative (GPEI).
This is a shared conversation. Sign in to Orris to start your own chat.